|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM366758810 |
| 003 |
DE-627 |
| 005 |
20250305154824.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240114s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.109894
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1222.xml
|
| 035 |
|
|
|a (DE-627)NLM366758810
|
| 035 |
|
|
|a (NLM)38185268
|
| 035 |
|
|
|a (PII)S1521-6616(24)00005-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Beckers, L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.01.2024
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a B cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting (RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological changes in peripheral blood of a real-world MS cohort after 6 and 12 months of ocrelizumab. All RRMS and most PPMS patients (15/20) showed treatment response. Ocrelizumab not only reduced CD20+ B cells, but also numbers of CD20+ T cells. Absolute numbers of monocytes, dendritic cells and CD8+ T cells were increased, while CD56hi natural killer cells were reduced after ocrelizumab. The residual B cell population shifted towards transitional and activated, IgA+ switched memory B cells, double negative B cells, and antibody-secreting cells. Delaying the treatment interval by 2-3 months increased mean B cell frequencies and enhanced naive B cell repopulation. Ocrelizumab reduced plasma levels of interleukin(IL)-12p70 and interferon(IFN)-α2. These findings will contribute to understanding ineffective treatment responses, dealing with life-threatening infections and further unravelling MS pathogenesis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a B cells
|
| 650 |
|
4 |
|a Extended interval dosing
|
| 650 |
|
4 |
|a High-dimensional flow cytometry
|
| 650 |
|
4 |
|a Multiple sclerosis
|
| 650 |
|
4 |
|a Ocrelizumab
|
| 650 |
|
4 |
|a Treatment response
|
| 650 |
|
7 |
|a ocrelizumab
|2 NLM
|
| 650 |
|
7 |
|a A10SJL62JY
|2 NLM
|
| 650 |
|
7 |
|a Immunologic Factors
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-12
|2 NLM
|
| 650 |
|
7 |
|a 187348-17-0
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 700 |
1 |
|
|a Baeten, P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Popescu, V
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Swinnen, D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cardilli, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hamad, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Van Wijmeersch, B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tavernier, S J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kleinewietfeld, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Broux, B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fraussen, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Somers, V
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 259(2024) vom: 06. Feb., Seite 109894
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:259
|g year:2024
|g day:06
|g month:02
|g pages:109894
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.109894
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 259
|j 2024
|b 06
|c 02
|h 109894
|